my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
27-04-2010: Helsinn Healthcare SA and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announced the launch of Aloxi(R) injection. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement between Taiho and Helsinn of January 2004, and its marketing approval was obtained on20 January 2010.
Chemotherapy-induced nausea and vomiting can be classified into acute nausea and vomiting which appears within 24 hours after chemotherapy administration, or into delayed nausea and vomiting which appears after 24 hours from chemotherapy administration up to 120 hours. In Japan, only limited efficacy for delayed nausea and vomiting has been shown with currently available agents.
With a single administration before chemotherapy (cisplatin, etc), Aloxi showed to be effective not only in acute nausea and vomiting, but also in delayed nausea and vomiting, in which currently available agents were not able to show adequate efficacy. Aloxi has a prolonged plasma half-life of approximately 40 hours, and possesses high binding affinity and selectivity towards the 5-HT3 receptors. Furthermore, use of Aloxi is recommended for the prevention of chemotherapy induced nausea and vomiting following Moderately Emetogenic Chemotherapy (non AC/EC) in the 2009 International Antiemetic Guideline of the European Society for Medical Oncology (ESMO)/ Multinational Association of Supportive Care in Cancer (MASCC).
Aloxi is approved in 63 countries worldwide, reaching global sales of more than400M USD(approx.36B yen) last year.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Zealand Pharma A/S and Helsinn announced that the first patients have been dosed in a Phase IIa study of elsiglutide (ZP1846) for the prevention of chemotherapy-induced diarrhea in cancer patients. Elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) agonist invented by Zea ... more
The 5-HT3 Receptor Antagonist Aloxi Launched in Japan
Helsinn Healthcare SA and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announced the launch of Aloxi(R) injection. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreem ... more
Helsinn announced the completion of its state of the art Stability Centre at its Helsinn Birex Pharmaceuticals facility in Dublin, Ireland. The new facility which has a total storage capacity of 24 cu meters, contains a range of stability chambers which will operate at ICH conditions of 25 ... more
Helsinn adopts a Multi-project Integrated Licensing strategy which focuses on taking valuable pharmaceutical compounds from an early clinical phase to a secure international market position and providing its partners with continuous scientific and market value. Helsinn has proven expertise ... more
Helsinn Birex Pharmaceuticals Ltd.
Helsinn's ability to supply packed finished product forms an important part of its complete service (product, marketing assistance, scientific development, and regulatory assistance) to its partners. Since 1997 these products have been manufactured in a modern facility in Damastown, West D ... more
The 5-HT3 Receptor Antagonist Aloxi Launched in Japan
Helsinn Healthcare SA and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announced the launch of Aloxi(R) injection. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreem ... more
Sanofi-aventis announced that it is returning its territory rights to Taiho Pharmaceutical Co., Ltd. Japan for the development and commercialization of the oral anticancer agent S-1. This termination follows the announcement by Taiho Pharmaceutical Co., Ltd of the Phase III study results w ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
